Drugs / NGM395
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04187339 | Feb → Oct 2020 | fatty liver disease, obesity disorder | NGM Biopharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NGM395 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04187339 ↗ |
| Route | Subcutaneous | “NGM395 Subcutaneous Injection” NCT04187339 ↗ |